Redox control of glutamine utilization in cancer

Cell Death and Disease

Volumn 5, Issue 12, 2014, Pages

  Alberghina, L ^a   Gaglio, D ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; AMINO ACID; ANTINEOPLASTIC AGENT; LIPID; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NNT PROTEIN, HUMAN;

AMINO ACID SYNTHESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARBOXYLATION; ELECTRON TRANSPORT; GLYCOLYSIS; HUMAN; IN VIVO STUDY; LIPOGENESIS; MITOCHONDRION; NEOPLASM; NONHUMAN; NONPHOTOCHEMICAL QUENCHING; PENTOSE PHOSPHATE CYCLE; PRECURSOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION; PATHOLOGY;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; GLUTAMINE; GLYCOLYSIS; HUMANS; LIPIDS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NAD; NADP; NADP TRANSHYDROGENASE, AB-SPECIFIC; NEOPLASMS; OXIDATION-REDUCTION; PENTOSE PHOSPHATE PATHWAY; REACTIVE OXYGEN SPECIES;

EID: 84926618247     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.513     Document Type: Article

References (103)

1. Warburg O. On the origin of cancer cells. Science (New York, NY) 1956; 123: 309-314.
2. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
3. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 2012; 15: 157-170.
4. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M et al. PET and PET/CT using 18 F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006; 11: 286-296.
5. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev 2003; 3: 11-22.
6. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
7. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev 2011; 11: 761-774.
8. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011; 7: 523.
9. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 2012; 22: 399-412.
10. Baracca A, Chiaradonna F, Sgarbi G, Solaini G, Alberghina L, Lenaz G. Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim Biophys Acta 2010; 1797: 314-323.
11. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013; 496: 101-105.
12. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149: 656-670.
13. Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One 2009; 4: e4715.
14. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
15. Murphy TA, Dang CV, Young JD. Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metab Eng 2013; 15: 206-217.
16. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natil Acad Sci USA 2008; 105: 18782-18787.
17. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178: 93-105.
18. Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013; 73: 4429-4438.
19. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107: 2037-2042.
20. Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P et al. Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab 2014; 19: 795-809.
21. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15: 110-121.
22. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol 2013; 9: 712.
23. Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer 2013; 12: 152.
24. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev 2011; 10: 671-684.
25. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013; 123: 3678-3684.
26. Thiele I, Swainston N, Fleming RM, Hoppe A, Sahoo S, Aurich MK et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol 2013; 31: 419-425.
27. Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007; 3: 124.
28. Metallo CM, Vander Heiden MG. Understanding metabolic regulation and its influence on cell physiology. Mol Cell 2013; 49: 388-398.
29. Hiller K, Metallo CM. Profiling metabolic networks to study cancer metabolism. Curr Opin Biotechnol 2013; 24: 60-68.
30. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 2012; 148: 1132-1144.
31. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci 2014; 39: 91-100.
32. Dang CV. Links between metabolism and cancer. Genes Dev 2012; 26: 877-890.
33. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY) 2009; 324: 1029-1033.
34. Li B, Simon MC. Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res 2013; 19: 5835-5841.
35. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010; 107: 7455-7460.
36. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010; 107: 7461-7466.
37. Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P et al. p73 regulates serine biosynthesis in cancer. Oncogene 2013; 33: 5039-5046.
38. Giacobbe A, Bongiorno-Borbone L, Bernassola F, Terrinoni A, Markert EK, Levine AJ et al. p63 regulates glutaminase 2 expression. Cell Cycle (Georgetown, Tex) 2013; 12: 1395-1405.
39. Velletri T, Romeo F, Tucci P, Peschiaroli A, Annicchiarico-Petruzzelli M, Niklison-Chirou MV et al. GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle (Georgetown, Tex) 2013; 12: 3564-3573.
40. Anastasiou D, Cantley LC. Breathless cancer cells get fat on glutamine. Cell Res 2012; 22: 443-446.
41. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011; 481: 380-384.
42. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014; 508: 108-112.
43. Calabrese C, Iommarini L, Kurelac I, Calvaruso MA, Capristo M, Lollini PL et al. Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab 2013; 1: 11.
44. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406-410.
45. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocy-toma and to familial paraganglioma. Am J Hum Genet 2001; 69: 49-54.
46. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov 3: 648-657.
47. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2011; 481: 385-388.
48. Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, Kovacs Z et al. Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep 2014; 7: 1679-1690.
49. Leonardi R, Subramanian C, Jackowski S, Rock CO. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 2012; 287: 14615-14620.
50. Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G. Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem 2013; 288: 12967-12977.
51. Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Mol Cancer 2010; 9: 293.
52. Neuzil J, Rohlena J, Dong LF. K-Ras and mitochondria: dangerous liaisons. Cell Res 2011; 22: 285-287.
53. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno-Sanchez R. The causes of cancer revisited: 'mitochondrial malignancy' and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy. Mol Aspects Med 2010; 31:145-170.
54. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107: 8788-8793.
55. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death Dis 2014; 5: e1065.
56. Zaidi N, Swinnen JV, Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res 2012; 72: 3709-3714.
57. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777.
58. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8: 311-321.
59. Cairns RA, Harris I, McCracken S, Mak TW. Cancer cell metabolism. Cold Spring Harb Symp Quant Biol 2011; 76: 299-311.
60. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 2014; 510: 298-302.
61. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011; 14: 443-451.
62. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011; 43: 869-874.
63. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011; 476: 346-350.
64. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci 2014; 39:191-198.
65. Lewis CA, Parker SJ, Fiske BP, McCloskey D, Gui DY, Green CR et al. Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol Cell2014; 55: 253-263.
66. Nijhout HF, Reed MC, Lam SL, Shane B, Gregory 3rd JF, Ulrich CM. In silico experimentation with a model of hepatic mitochondrial folate metabolism. Theor Biol Med Model 2006; 3: 40.
67. Ye J, Fan J, Venneti S, Wan YW, Pawel BR, Zhang J et al. Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 2014; e-pub ahead of print 3 September 2014; doi:10.1158/2159-8290.CD-14-0250.
68. Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci 2014; 39: 347-354.
69. Eden E, Geva-Zatorsky N, Issaeva I, Cohen A, Dekel E, Danon T et al. Proteome half-life dynamics in living human cells. Science (New York, NY) 2011; 331: 764-768.
70. Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab 2013; 17: 491-506.
71. Gerner EW, Meyskens Jr FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4: 781-792.
72. Phang JM, Liu W. Proline metabolism and cancer. Front Biosci (Landmark edition) 2012; 17:1835-1845.
73. Bowlby SC, Thomas MJ, D'Agostino Jr RB, Kridel SJ. Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS One 2012; 7: e40195.
74. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009; 20:130-138.
75. Matheny CJ, Wei MC, Bassik MC, Donnelly AJ, Kampmann M, Iwasaki M et al. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chem Biol2013; 20:1352-1363.
76. Chini CC, Guerrico AM, Nin V, Camacho-Pereira J, Escande C, Barbosa MT et al. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. Clin Cancer Res 2013; 20:120-130.
77. Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem 2013; 288: 3500-3511.
78. Drevs J, Loser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 2003; 23: 4853-4858.
79. Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ et al. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Invest 2013; 123:1068-1081.
80. Nikiforov A, Dolle C, Niere M, Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem 2011; 286: 21767-21778.
81. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436-7442.
82. Grozio A, Sociali G, Sturla L, Caffa I, Soncini D, Salis A et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J Biol Chem 2013; 288: 25938-25949.
83. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F et al. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 2010; 285: 34106-34114.
84. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509.
85. Alberghina L, Gaglio D, Moresco RM, Gilardi MC, Messa C, Vanoni M. A systems biology road map for the discovery of drugs targeting cancer cell metabolism. Curr Pharm Des 2014; 20: 2648-2666.
86. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 2012; 15: 827-837.
87. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev 2013; 12: 829-846.
88. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 2007; 406: 407-414.
89. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70: 8981-8987.
90. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532.
91. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 2014; 13: 890-901.
92. Antoniewicz MR. 13C metabolic flux analysis: optimal design of isotopic labeling experiments. Curr Opin Biotechnol 2013; 24: 1116-1121.
93. Antoniewicz MR. Using multiple tracers for 13C metabolic flux analysis. Methods Mol Biol Clifton, NJ 2013; 985: 353-365.
94. Zhang J, Ahn WS, Gameiro PA, Keibler MA, Zhang Z, Stephanopoulos G. 13C isotopeassisted methods for quantifying glutamine metabolism in cancer cells. Methods Enzymol 2014; 542: 369-389.
95. Sugiura Y, Honda K, Kajimura M, Suematsu M. Visualization and quantification of cerebral metabolic fluxes of glucose in awake mice. Proteomics 2014; 14: 829-838.
96. Kelly AD, Breitkopf SB, Yuan M, Goldsmith J, Spentzos D, Asara JM. Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma. PLoS One 2011; 6: e25357.
97. Shestov AA, Barker B, Gu Z, Locasale JW. Computational approaches for understanding energy metabolism. Wiley Interdiscip Rev 2013; 5: 733-750.
98. Frank SA. Age of cancer incidence. Dynamics of Cancer: Incidence, Inheritance, and Evolution. Princeton, NJ: Princeton University Press, 2007, pp 17-35.
99. Stefanatos R, Sanz A. Mitochondrial complex I: a central regulator of the aging process. Cell Cycle (Georgetown, Tex 2011; 10: 1528-1532.
100. Wu LE, Gomes AP, Sinclair DA. Geroncogenesis: metabolic changes during aging as a driver of tumorigenesis. Cancer Cell 2014; 25: 12-19.
101. Yizhak K, Le Devedec SE, Rogkoti VM, Baenke F, de Boer VC, Frezza C et al. A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. Mol Syst Biol 2014; 10: 744.
102. Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis 2013; 4: e877.
103. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013; 123: 3685-3692.